

**Cancer Cell, Volume 38**

## **Supplemental Information**

### **Cancer Care Disparities**

**during the COVID-19 Pandemic:**

### **COVID-19 and Cancer Outcomes Study**

**Andrew L. Schmidt, Ziad Bakouny, Sheena Bhalla, John A. Steinharter, Douglas A. Tremblay, Mark M. Awad, Alaina J. Kessler, Robert I. Haddad, Michelle Evans, Fiona Busser, Michael Wotman, Catherine R. Curran, Brittney S. Zimmerman, Gabrielle Bouchard, Tomi Jun, Pier V. Nuzzo, Qian Qin, Laure Hirsch, Jonathan Feld, Kaitlin M. Kelleher, Danielle Seidman, Hsin-Hui Huang, Heather M. Anderson-Keightly, Sarah Abou Alaiwi, Talia D. Rosenbloom, Penina S. Stewart, Matthew D. Galsky, Toni K. Choueiri, and Deborah B. Doroshov**

**Table S1.** Adjusted odds ratios and 95% confidence intervals from the multivariable logistic regression model.

		Any decrease in All Visits	Any decrease in In-Person Visits	Any decrease in Telehealth Visits	COVID-19 Diagnosis	Treatment Delays	Delays in Diagnostic Imaging	Change in Treatment Secondary to Pandemic
	Non-missing (N)	2066	2066	2066	2069	2064	2039	2068
Independent Variable	Levels	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)
Race	Non-Hispanic White	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
	Non-Hispanic Black	1.10 (0.83-1.45)	0.93 (0.70-1.23)	0.69 (0.50-0.94)	1.86 (1.10-3.11)	1.26 (0.84-1.88)	0.66 (0.31-1.30)	0.85 (0.40-1.68)
	Hispanic	1.34 (1.02-1.77)	1.10 (0.83-1.46)	0.71 (0.51-0.98)	3.19 (2.00-5.10)	1.53 (1.03-2.26)	1.51 (0.85-2.59)	1.50 (0.79-2.74)
	Other	1.06 (0.75-1.51)	0.93(0.62-1.32)	0.90 (0.60-1.32)	0.25 (0.04-0.84)	0.78 (0.41-1.38)	1.24 (0.57-2.47)	1.20 (0.50-2.57)
Site	MSSM	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
	DFCI	1.16 (0.88-1.53)	1.39 (1.06-1.84)	3.18 (2.35-4.35)	0.24 (0.11-0.48)	0.31 (0.19-0.51)	0.49 (0.27-0.90)	0.28 (0.12-0.56)
Tumor Status	Localized, Locally Advanced, or Stable	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
	Metastatic or Active	1.22 (0.99-1.51)	1.33 (1.08-1.64)	1.12 (0.89-1.39)	1.71 (1.06-2.80)	0.97 (0.69-1.36)	1.87 (1.09-3.33)	0.54 (0.32-0.91)
	Complete Response or NED	0.84 (0.64-1.10)	0.81 (0.63-1.06)	0.52 (0.38-0.71)	1.25 (0.70-2.23)	0.80 (0.51-1.25)	2.88 (1.54-5.51)	0.37 (0.16-0.77)
Current Treatment	No	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)
	Yes	1.76 (1.43-2.17)	2.03 (1.65-2.49)	1.56 (1.25-1.96)	1.37 (0.88-2.19)	3.04 (2.07-4.58)	1.34 (0.83-2.20)	4.83 (2.32-11.79)
Main Tumor	Genitourinary Malignancy	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	1 (Ref)	Not included (insufficient events)
	Breast Malignancy	0.82 (0.57-1.18)	0.70 (0.49-1.00)	0.87 (0.56-1.34)	0.60 (0.27-1.32)	0.57 (0.32-1.03)	0.38 (0.15-0.92)	Not included (insufficient events)
	Head and Neck Malignancy	1.99 (1.39-2.86)	1.44 (1.00-2.07)	0.98 (0.66-1.44)	1.05 (0.33-2.79)	0.48 (0.18-1.10)	1.37 (0.52-3.23)	Not included (insufficient events)
	Hematological Malignancy	1.51 (1.09-2.10)	1.78 (1.28-2.47)	2.69 (1.88-3.88)	1.71 (0.91-3.35)	1.52 (0.93-2.52)	1.00 (0.50-2.05)	Not included (insufficient events)
	Thoracic Malignancy	2.20 (1.63-2.97)	2.08 (1.53-2.86)	1.16 (0.85-1.57)	1.30 (0.59-2.77)	1.45 (0.85-2.44)	2.30 (1.19-4.45)	Not included (insufficient events)
	Gastrointestinal Malignancy	1.81 (1.21-2.72)	1.71 (1.14-2.58)	1.51 (0.95-2.40)	0.70 (0.28-1.67)	0.98 (0.53-1.81)	0.78 (0.28-1.97)	Not included (insufficient events)
	Solid Tumor	1.27 (0.82-1.95)	1.16 (0.75-1.77)	1.13 (0.69-1.84)	0.99 (0.39-2.35)	0.74 (0.35-1.50)	1.31 (0.53-3.08)	Not included (insufficient events)

MSSM; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, DFCI; Dana-Farber Cancer Institute, NED; no evaluable disease, aOR; adjusted odds ratio, Ref; reference